Belgian health research consultancy specialising in real-world evidence and remote clinical trial design within IMI2 consortia.
Vital Transformation is a Belgian health research consultancy specialising in clinical trial methodology and the use of real-world evidence in medicine development and regulatory decision-making. Their work sits at the intersection of clinical research design, regulatory science, and patient-centric trial innovation — contributing expertise to how new medicines are evaluated and approved. They have been involved in the shift from traditional site-based clinical trials toward decentralised, remote models that reduce patient burden and broaden trial access. Operating as a small specialist firm, they punch above their weight by embedding in large, multi-stakeholder EU consortia funded under the Innovative Medicines Initiative.
Participation in the GetReal Initiative (2018–2021), an IMI2 project explicitly focused on incorporating real-world evidence into regulatory and health technology assessment processes.
Participation in Trials@Home (2019–2025), a Centre of Excellence dedicated to designing and implementing remote, decentralised clinical trial models.
Both projects address fundamental questions in how clinical trials are designed, conducted, and their results used — suggesting a cross-cutting methodological contribution across the portfolio.
Vital Transformation entered H2020 funding through the GetReal Initiative in 2018, focusing on how real-world data can strengthen the evidentiary basis for regulatory and reimbursement decisions — a largely policy and methodology-oriented challenge. By 2019 their engagement had shifted toward the operational and infrastructural transformation of clinical trials themselves, with Trials@Home targeting the practical delivery of remote, decentralised trial models. This represents a progression from "how should evidence be used?" toward "how should trials be run?" — moving closer to the actual mechanics of clinical research execution.
Vital Transformation is moving toward the operational frontier of clinical research — decentralised trials and digital health infrastructure — which positions them well for partnerships in patient-centric trial design and health data systems.
Vital Transformation has participated exclusively as a consortium partner, never as a coordinator, suggesting they contribute specialist expertise rather than drive project leadership. Both of their projects are large, multi-partner consortia — the 44 unique partners across 13 countries from just two projects indicates they are comfortable operating within complex, pan-European research alliances typical of IMI2 programmes. This profile points to a focused specialist that integrates into established consortia where their niche expertise in trial methodology adds clear value.
Despite only two projects, Vital Transformation has built a network of 44 unique partners across 13 countries — a reflection of the large, multi-stakeholder consortia that characterise IMI2 funding. Their reach is genuinely European, with no indication of a strong geographic concentration beyond their Belgian base.
Vital Transformation is a rare example of a very small private firm holding its own in IMI2 consortia, which are typically dominated by large pharma companies, academic medical centres, and regulatory agencies. This suggests they bring a differentiated methodological or advisory perspective that large institutions value but cannot easily replicate internally. For consortium builders in clinical research, they offer an agile, specialist voice on trial design and evidence strategy without the overhead of a large partner.
